[A contribution to the rate of side-effects of hepatotropic contrast media. A clinical comparative study of iodoxamate (Endomirabil) and ioglycamid (Bilivistan) (author's transl)].
The new substance Iodoxamate (Endomirabil) is a hepatotropic contrast medium. In a clinical comparative study, the contrast of the biliary ducts and gall bladder is equivalent compared with Ioglycamid (Bilivistan). Assuming equal conditions of injection and in conformity with animal experimental studies, the rate of side effects of Iodoxamate is distinctly lower than that of the referring substance Iolgycamid (Bilivistan).
D002758:Cholangiography; D002765:Cholecystography; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007471:Ioglycamic Acid / Q000009:adverse effects*; D011786:Quality Control; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007471:Ioglycamic Acid
Beitrag zur Nebenwirkungsrate hepatotroper Kontrastmittel. Klinische Vergleichsuntersuchung von Iodoxamat (Endomirabil) und Ioglycamid (Bilivistan)